581076-64-4

Basic information

• Product Name: 2-(5-amino-2-methylphenyl)guanidine
• Synonyms: 1-(5-Amino-2-methylphenyl)guanidine; guanidine, N-(5-amino-2-methylphenyl)-
• CAS NO: 581076-64-4
• Molecular Formula: C₈H₁₂N₄
• Molecular Weight: 164.2077
• Mol File: 581076-64-4.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 416.5°C at 760 mmHg
• Flash Point: 205.7°C
• Density: 1.29g/cm³
• Vapor Pressure: 3.79E-07mmHg at 25°C
• Refractive Index: 1.635
• CAS DataBase Reference: 2-(5-amino-2-methylphenyl)guanidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(5-amino-2-methylphenyl)guanidine(581076-64-4)
• EPA Substance Registry System: 2-(5-amino-2-methylphenyl)guanidine(581076-64-4)

Safety Data

• Hazardous Substances Data: 581076-64-4(Hazardous Substances Data)

Usage

General Description

2-(5-amino-2-methylphenyl)guanidine is a chemical compound with the molecular formula C8H11N5. It is a guanidine derivative, which is a class of organic compounds that contain a guanidine functional group. This chemical is used in the production of pharmaceuticals and as a reagent in organic synthesis. It has been studied for its potential applications in the treatment of neurological disorders and as an anticonvulsant. Additionally, 2-(5-amino-2-methylphenyl)guanidine may have antibacterial and antifungal properties, making it a valuable compound for research and drug development. Overall, this chemical has a range of potential applications in the fields of medicine and science.

Upstream product

• 99-55-8 2-methyl-5-nitroaniline 
• 152460-07-6 1-(2-methyl-5-nitrophenyl)guanidine 

Downstream Products

• 152460-10-1 6-methyl-1-N-(4-(pyridin-3-yl)pyrimidin-2-yl)benzene-1,3-diamine 
• 1026747-16-9 1-(5-amino-2-methylphenyl)-3-[3-oxo-3-(3-pyridinyl)-1-prop-1-enyl]guanidine 
• 641615-40-9 N*3*-[4-(6-chloropyridin-3-yl)-pyrimidin-2-yl]-4-methylbenzene-1,3-diamine 

Relevant articles and documents

Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases

Urea-based analogues of STI571 are described possessing structural features which can differentiate between Abl/Bcr-Abl and PDGFR kinase inhibition. The constitutively active Abl kinase activity of the Bcr-Abl oncoprotein is causative for chronic myelogenous leukemia. Urea derivatives, structurally related to the therapeutic agent STI571, have been identified, which potently inhibit the tyrosine kinase activity of recombinant Abl. In particular a dimethylamino-aniline derivative (18) inhibited c-Abl transphosphorylation with an IC50 value of 56 nM. Although this activity was not translated into cellular activity against the constitutively activated oncogenic Bcr-Abl, a number of compounds from this series potently inhibited cellular PDGFR autophosphorylation. It was also possible to differentiate between c-Abl and PDGFR kinase inhibition, with compound 22 being selective towards Abl and 23 selective for PDGFR.